VitaSpanCare Programme · Hainan Boao Lecheng
不只控制類風濕，更修復它已損壞的關節
For patients whose rheumatoid arthritis has resisted conventional drugs or biologics, umbilical cord mesenchymal stem cell therapy (hUC-MSC) offers a fundamentally different approach: reset the immune system and repair damaged tissue — at the same time.
Request a Suitability Assessment How It WorksThe Treatment Gap
現有藥物只能抑制發炎，無法修復關節損傷
Rheumatoid arthritis is often described as the "cancer that won't kill you." Left uncontrolled, it erodes cartilage, destroys bone, and — over 15 years — leaves 63% of patients permanently disabled.
Conventional DMARDs and biologics work by interrupting the inflammatory signal. They are valuable, but they have a ceiling: they cannot regenerate the synovium or cartilage that has already been damaged. And for roughly 40% of difficult-to-treat cases, multiple lines of biologics eventually stop working.
This is the gap that stem cell therapy is designed to address — not as a first line, but as the option that becomes meaningful when other approaches have run their course.
The Damage Trap
Drugs control, but cannot rebuild
Even well-managed RA accumulates joint destruction over time. X-rays showing bone erosion signal damage that no current drug can reverse.
The Resistance Problem
~30% of biologics lose effect within 2 years
Secondary failure leaves patients cycling through expensive options, each with its own side-effect profile and diminishing returns.
The Toxicity Burden
Long-term immunosuppression has a price
Liver and kidney stress, infection risk, and pregnancy contraindications accumulate with years of DMARD use — especially for younger patients.
Mechanism
雙通道治療：免疫重建 + 組織修復
免疫重新校準
hUC-MSCs suppress the overactivated T and B cells driving joint inflammation, promote regulatory T-cell (Treg) generation, and restore the M1/M2 macrophage balance — addressing the immune dysregulation at the root of RA, not just its downstream effects.
滑膜與軟骨修復
Stem cells secrete VEGF, TGF-β, and other trophic factors that directly stimulate synovial tissue repair and cartilage regeneration. This capacity for structural restoration is something no existing drug — biologic or targeted DMARD — can replicate.
骨骼重塑支持
By suppressing osteoclast activity and promoting osteoblast differentiation, hUC-MSCs help slow the bone erosion that characterises progressive RA — a structural benefit beyond symptom management.
持久療效
Unlike daily or weekly medications, hUC-MSC therapy works through a sustained biological process. Three-year follow-up data from clinical studies show stable remission in responsive patients — with some achieving partial or full drug reduction.
Why This Approach
Repair, Not Just Suppress
修復，而非單純抑制
The only currently available approach with documented capacity to repair damaged synovium and cartilage — not simply pause the inflammation damaging them.
Works When Biologics Don't
生物製劑失效後的選項
Targets the upstream immune dysregulation — Treg pathways — rather than blocking individual cytokines, making it effective even after multiple biologic failures.
Minimal Toxicity Profile
極低毒性
No liver or kidney toxicity detected in pre/post treatment blood panels (P>0.05). No serious adverse events in documented follow-up. Particularly relevant for patients who have accumulated years of DMARD toxicity burden.
Drug Reduction Potential
減藥可能性
In a subset of responsive patients — particularly those with high anti-CCP antibody titres — improved immune homeostasis has allowed reduction or discontinuation of maintenance medication.
Outpatient IV Infusion
門診靜脈輸注
Administered as an outpatient intravenous infusion — no surgery, no general anaesthesia. Treatment day is followed by 1–3 days of observation, then the patient returns home.
Sustained Remission
持續緩解
Three-year follow-up in a 172-patient study shows stable reduction in HAQ and DAS28 scores, alongside measurable decreases in CRP, IL-6, and TNF-α inflammatory markers.
Patient Suitability
哪些患者適合這個療程
Diagnosed RA patients aged 18–75 with confirmed rheumatoid arthritis
18–75歲，已確診類風濕關節炎Patients with inadequate response to conventional DMARDs or biologics
對傳統改善病情藥物或生物製劑療效不佳Patients with X-ray evidence of bone erosion seeking structural repair
影像顯示骨侵蝕，尋求結構性修復Younger patients or those planning pregnancy who need to avoid long-term immunosuppressants
年輕患者或計劃生育者，需避免長期免疫抑制劑Patients with accumulated toxicity burden from years of DMARD treatment
長期服藥導致肝腎功能受損、毒副作用積累Contraindications — this programme is not suitable for
Final eligibility is determined by the clinical team following review of your full medical history and recent test results. VitaSpanCare provides a complimentary pre-screening review before any commitment.
Clinical Evidence
安全性與有效性數據
172 patients
An expanded study of 172 RA patients treated with hUC-MSC showed significant reductions in HAQ and DAS28 disease activity scores, alongside measurable decreases in inflammatory markers CRP, IL-6, and TNF-α. Treg cell elevation correlated with clinical improvement, offering a proposed immunological biomarker for treatment response.
3-yr follow-up
Three-year follow-up of the initial 17-patient pilot cohort (single-dose: 16 patients; dual-dose: 1 patient; dose 0.2–0.4 × 10⁶ cells/kg) showed stable, sustained remission with no deterioration in liver or kidney function at any follow-up point. Safety profile confirmed: no serious adverse events observed.
How It Happens
從初步諮詢到治療，以及後續追蹤
Pre-screening
Submit medical history & recent reports. VitaSpanCare reviews eligibility — no commitment required.
病歷初審Medical Consultation
Online or in-person consultation with the clinical team. Local pre-treatment tests arranged.
線上或線下問診Cell Preparation
Personalised stem cell batch prepared over 5–7 days. Travel & accommodation coordinated by VitaSpanCare.
細胞制備（5–7天）Treatment at Lecheng
Outpatient IV infusion at the Hainan Boao Lecheng facility. 1–3 days observation. Typically a 5-day trip.
海南博鰲樂城治療Follow-up Care
Structured follow-up protocol at intervals defined by your clinical team. Remote consultation supported.
定期隨訪復診Why Hainan Boao Lecheng
使這一療法得以實現的監管框架
Hainan Boao Lecheng International Medical Tourism Pioneer Zone is China's designated pilot zone for advanced clinical translation — operating under a special regulatory framework that permits access to therapies and medical technologies not yet widely approved or available in mainland clinical settings.
For patients outside China, this matters: hUC-MSC therapy for RA is not commercially available in most countries. Lecheng provides legitimate, regulated access — through approved institutions — to a therapy that would otherwise require participation in an early-phase clinical trial to access anywhere in the world.
VitaSpanCare holds cooperative status with the Lecheng Management Bureau and works with institutions operating under the zone's special clinical translation permissions.
不確定自己是否適合？先做免費初步評估
Share your diagnosis and recent reports with us. Our team reviews them and gives you a plain-language assessment of suitability — at no cost and with no obligation to proceed.
填寫以下資料，我們將盡快與您聯絡
